No Data
Pulike Biological Engineering, Inc. 2024 Annual Report
Summary of Pulike Biological Engineering, Inc. Annual Report for 2024.
Pulike Biological Engineering, Inc. Q1 report for 2025.
Pulike Biological Engineering, Inc. (603566.SH): Net income in 2024 is expected to decline by 46.82% year-on-year, with a plan to distribute 4 yuan per 10 shares.
Gelonghui reported on April 24 that Pulike Biological Engineering, Inc. (603566.SH) announced its 2024 annual report, with revenue of 1.04 billion yuan, a year-on-year decrease of 16.77%. The net income attributable to shareholders of the listed company is 92.806 million yuan, a year-on-year decrease of 46.82%. A cash dividend of 4 yuan will be distributed for every 10 shares to all shareholders.
Pulike Biological Engineering, Inc. (603566.SH): In the first quarter, the net income was 52.9077 million yuan, a year-on-year increase of 93.75%.
Gelonghui, April 24, Pulike Biological Engineering, Inc. (603566.SH) announced its first quarter report, with revenue of 0.279 billion yuan, a year-on-year increase of 18.32%. The net income attributable to shareholders of the listed company is 52.9077 million yuan, a year-on-year increase of 93.75%. The net income attributable to shareholders of the listed company after deducting non-recurring gains and losses is 48.897 million yuan, a year-on-year increase of 84.27%.
Huachuang Securities: In the first quarter, the issuance of vaccine batches increased significantly, and the price of macrocyclic lactone veterinary medicine Active Pharmaceutical Ingredients continues to rise.
The demand for animal health products is gradually recovering, and by 2025, the breeding sector is expected to maintain profitability. The continuity of demand for animal health products may be ensured, and the Operation in the animal health Sector is gradually establishing a turning point.
Benign Growth For Pulike Biological Engineering, Inc. (SHSE:603566) Underpins Stock's 27% Plummet
